|

Allogeneic NK Cells Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Paolo Caimi, MD1
  • Artiva Biotherapeutics, Inc.1

Indications

  • Sjogrens Disease1
  • Myositis1
  • IIM1
  • Idiopathic Inflammatory Myopathies (IIMs)1
  • Refractory Rheumatoid Arthritis (RA)1

Tuscaloosa, Alabama1 trial

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Artiva Investigational Site Tuscaloosa

Phase 2

Cleveland, Ohio1 trial

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.